NovaBridge Biosciences
givastomig
gastric cancer
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for givastomig in gastric cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“NovaBridge reported positive Phase 1b dose expansion data in January 2026 demonstrating:”